Prothena Corp PLC (PRTA)
54.98
-2.14 (-3.75%)
USD |
NASDAQ |
Jan 30, 16:00
54.98
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.660B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 81.62% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 514.07 |
| Price to Book Value | 6.573 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 90.85% |
News
Headline
Wire
Time (ET)
SA Breaking News
01/27 12:04
Yahoo
01/15 09:01
MT Newswires
01/13 08:03
SA Breaking News
01/06 15:19
MT Newswires
12/21 09:35
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/17/2023* | -- | Results | Q4 2022 | -- | -0.45 | -- | |
| 02/17/2023* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.97 | -0.62 | -56.70% | |
| 08/08/2022 | -- | Results | Q2 2022 | -0.88 | -0.53 | -66.77% | |
| 05/05/2022 | -- | Results | Q1 2022 | -0.78 | -0.64 | -22.28% | |
| 02/17/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 02/17/2022 | -- | Results | Q4 2021 | -0.71 | -0.44 | -62.83% | |
| 11/04/2021 | -- | Results | Q3 2021 | 2.13 | 2.24 | -4.70% |
*Estimated Date/Time
Earnings
Profile
Edit
| Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). |
| URL | https://www.prothena.com |
| Investor Relations URL | https://ir.prothena.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 17, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
| Revenue (TTM) | 5.154M |
| Total Expenses (TTM) | 169.73M |
| Net Income (TTM) | -156.48M |
| Total Assets (Quarterly) | 554.44M |
| Total Liabilities (Quarterly) | 149.79M |
| Shareholders Equity (Quarterly) | 404.65M |
Ratings
Profile
Edit
| Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). |
| URL | https://www.prothena.com |
| Investor Relations URL | https://ir.prothena.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 17, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| PRTA Tweets |